Alira Health Expands Its Global Clinical and Data Capabilities Through the Acquisition of CROS NT

CROS NT’s expertise in biometrics and clinical operations in Europe enhances Alira Health’s lifecycle of healthcare advisory services.

News
Category:
Published on:
June 8, 2021

FRAMINGHAM, Mass.–(BUSINESS WIRE)– Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory services firm, announced that it has acquired CROS NT (www.crosnt.com), a data-driven Contract Research Organization (CRO) headquartered in Italy with offices across Europe and the United States. CROS NT provides high quality, cost-effective biometrics and innovative solutions to help clients develop and deliver therapeutics and diagnostics that improve patient lives around the world. This acquisition brings additional expertise to Alira Health’s full spectrum of advisory and implementation services that help providers, payers and suppliers uncover opportunity, accelerate innovation, and improve outcomes for patients.

“We are extremely pleased to acquire CROS NT’s Biometrics services globally. The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said Gabriele Brambilla, Chief Executive Officer at Alira Health. “The addition of CROS NT will also enable Alira Health to expand our direct clinical operations in Europe. We embrace CROS NT’s commitment and passion to being a visionary in clinical research and are proud to welcome CROS NT CEO, Paolo Morelli, and his team to our fast-growing company.”

“CROS NT is delighted to join Alira Health to better serve our clients by providing a complete portfolio of services and solutions. We are excited to contribute to Alira Health’s mission of healthcare transformation, creating value for patients,” said Paolo Morelli, CEO of CROS NT. “Our experienced team of professionals will deliver value through our combined services, accelerating innovation and delivering tomorrow’s standard of care to patients.”

Paolo Morelli will join Alira Health’s leadership as Executive Vice President, Biometrics, and will lead the growth of Alira Health’s Data Science services.

About CROS NT:

CROS NT is a global biometrics service provider with 28+ years of experience in business, focused on clinical and observational trials. In addition, we support our clients with a full-service clinical offering delivered through a network of trusted partners.

CROS NT has offices in Bologna and Verona, Italy; London, England; Chapel Hill, NC, U.S.

 

 

To learn more about Alira Health

Contact us

Related news

Publications September 16, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Publications September 7, 2022
The Promise and Reality of Decentralized and Hybrid Clinical Trials in Europe Today
To understand the challenges related to hybrid and decentralized trials and ways to overcome them, we spoke with Dr. Hervé Solatges, Product Management, Evidence, and Innovation (DCT(...)
Clinical Decentralized Clinical Trials Hybrid Clinical Trials
Publications September 5, 2022
Taking In-Licensed Biologics to Market: Challenges, Complexities, and Ways to Overcome Them
Taking a biologic through drug development to market is highly complex and filled with challenges. To understand these challenges, their implications and how to overcome them, we spoke(...)
Biologics Clinical Drug Development
Events August 10, 2022
DPHARM
We are pleased to announce that we will be sponsoring and attending DPHARM, a unique event focused on the latest innovations that modernize clinical trials.
Clinical Decentralized Clinical Trials DPHARM Patient Centric
Publications August 2, 2022
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections.
Clinical CMC Vaccines
Multimedia May 19, 2022
Fireside Chat Replay: Latest Developments in Oncology Supportive Care
In this fireside chat, we sit down with two medical experts in oncology and discuss some of the fascinating developments that are happening in the oncology supportive care field.
Clinical
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.